{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-104557","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2024-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.617600+00:00","generated_at":"2026-05-31T05:56:00.421196+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Relay reports positive interim RLY-2608 data: 9.2mo PFS in PI3Kα-mutated breast cancer","bullets":["Median PFS 9.2 months (all mutations) and 10.3 months (kinase mutations) at RP2D in heavily pre-treated patients without PTEN/AKT co-mutations.","ORR of 33% overall and 53% in kinase mutations; CBR 57%; tumor reductions in 73% of measurable patients.","Favorable tolerability: 95% median dose intensity, only 2 discontinuations due to TRAEs, 1 Grade 3 hyperglycemia, no Grade 4-5 TRAEs.","Lirafugratinib: FDA suggests file NDA in cholangiocarcinoma first, then tumor-agnostic sNDA; company seeks global partner.","Cash runway ~$688M into H2 2026; plan to initiate 2L pivotal study of RLY-2608 in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-104557","json":"https://secwatch.observer/filing/0000950170-24-104557.json","markdown":"https://secwatch.observer/filing/0000950170-24-104557.md","text":"https://secwatch.observer/filing/0000950170-24-104557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024104557/0000950170-24-104557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024104557/rlay-20240909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:56:00.421196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}